Chromium Picolinate Regulates Bone Metabolism and Prevents Bone Loss in Diabetic Rats
Molecules · 2024
DOI: 10.3390/molecules29050924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Hongxing Zheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong 723000, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Bone Diseases, Metabolic, Osteoporosis, Picolinic Acids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: project from Qinba State Key Laboratory of Biological Re-sources and Eco-Environment, Science and Technology Department of Shaanxi Province Scientists + Engineers Team Construction Project, Project of Shaanxi Provincial Department of Science and Technology.
Abstract (Originalsprache)
Diabetic osteoporosis (DOP) is an abnormal metabolic disease caused by long-term hyperglycemia. In this study, a model rat of streptozotocin (STZ)-induced diabetes was established, and chromium picolinate (5 mg·kg−1) was given; the changes in blood glucose and body weight were detected before and after administration; and bone mineral density (BMD), bone morphology, bone turnover markers, inflammatory cytokines, and oxidative stress indicators were observed in each group. We found that after chromium picolinate (CP) intervention for 8 weeks, the blood glucose level was decreased; the BMD, the bone histomorphology parameters, and the pathological structure were improved; the expression of bone resorption-related proteins was downregulated; and the expression of bone formation-related proteins was upregulated. Meanwhile, serum antioxidant activity was increased, and inflammatory cytokine levels were decreased. In conclusion, CP could alleviate DOP by anti-oxidation, inhibition of bone turnover, anti-inflammation, and regulation of the OPG/RANKL/RANK signaling pathway. Therefore, CP has important application values for further development as a functional food or active medicine in DOP treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong 723000, China.
- State Key Laboratory of Qinba Biological Resources and Ecological Environment, Hanzhong 723000, China.
- Shaanxi Black Organic Food Engineering Technology Research Center, Hanzhong 723000, China.
- Qinba Mountain Area Collaborative Innovation Center of Bioresources Comprehensive Development, Hanzhong 723000, China.
- Shaanxi Provincial Key Laboratory of Resource Biology, Hanzhong 723001, China.
- Shaanxi Migukang Biotechnology Company, Xi'an 710018, China.
Förderung
- project from Qinba State Key Laboratory of Biological Re-sources and Eco-Environment
- Science and Technology Department of Shaanxi Province Scientists + Engineers Team Construction Project
- Project of Shaanxi Provincial Department of Science and Technology
- Key Research and Development Project of Shaanxi Province
- Young Talent Fund of Association for Science and Technology in Shaanxi
- Qinba State Key Laboratory of Biological Re-sources and Eco-Environment
- Shaanxi Provincial Department of Science and Technology
- Shaanxi Provincial Department of Education Service Local Special Project
Zitieren
APA
Zheng, H., Yan, W., Shao, M., & Qi, S. (2024). Chromium Picolinate Regulates Bone Metabolism and Prevents Bone Loss in Diabetic Rats. Molecules. https://doi.org/10.3390/molecules29050924
Vancouver
Zheng H, Yan W, Shao M, Qi S. Chromium Picolinate Regulates Bone Metabolism and Prevents Bone Loss in Diabetic Rats. Molecules. 2024. doi:10.3390/molecules29050924
BibTeX
@article{Zheng2024,
author = {Zheng, Hongxing and Yan, Wenrui and Shao, Mengli and Qi, Shanshan},
title = {Chromium Picolinate Regulates Bone Metabolism and Prevents Bone Loss in Diabetic Rats},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29050924}
}
EUVIMED